| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CLDN9 |
| Uniprot No | O95484 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-217aa |
| 氨基酸序列 | MASTGLELLGMTLAVLGWLGTLVSCALPLWKVTAFIGNSIVVAQVVWEGLWMSCVVQSTGQMQCKVYDSLLALPQDLQAARALCVIALLLALLGLLVAITGAQCTTCVEDEGAKARIVLTAGVILLLAGILVLIPVCWTAHAIIQDFYNPLVAEALKRELGASLYLGWAAAALLMLGGGLLCCTCPPPQVERPRGPRLGYSIPSRSGASGLDKRDYV |
| 预测分子量 | 24.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CLDN9重组蛋白的3篇文献概览(信息基于公开研究总结，非真实文献)：
---
1. **文献名称**: "Recombinant CLDN9 Expression in Cancer Cell Lines Enhances Chemosensitivity"
**作者**: Kim S, et al.
**摘要**: 研究通过重组CLDN9蛋白在卵巢癌细胞中的过表达，发现其能增加细胞对顺铂的敏感性，可能通过调节紧密连接通透性促进药物内流。
2. **文献名称**: "Structural Characterization of Human CLDN9 Recombinant Protein Using Cryo-EM"
**作者**: Zhang Y, et al.
**摘要**: 首次解析了重组CLDN9蛋白的冷冻电镜结构，揭示了其胞外环区独特的空间构象，为靶向CLDN9的抗体或小分子药物设计提供依据。
3. **文献名称**: "CLDN9 Recombinant Protein as a Biomarker for Hearing Loss in Mouse Models"
**作者**: Nakano Y, et al.
**摘要**: 在小鼠模型中验证重组CLDN9蛋白对内耳毛细胞屏障功能的修复作用，表明其可能成为遗传性耳聋的潜在治疗靶点。
---
注：以上为模拟文献摘要，实际研究需通过PubMed或Sci-Hub等平台检索真实文献(如PMID: 33168922等可能与CLDN9相关)。
CLDN9 (Claudin-9) is a member of the claudin family, a group of transmembrane proteins critical for forming tight junctions—specialized cell-cell adhesion structures that regulate paracellular permeability and maintain polarity in epithelial and endothelial tissues. Structurally, CLDN9 contains four transmembrane domains, two extracellular loops, and intracellular N- and C-termini. Its extracellular loops mediate homotypic or heterotypic interactions with other claudins, contributing to selective ion transport and barrier function.
CLDN9 is notably expressed in specific tissues, including the inner ear, liver, and kidney. In the cochlea, it plays a vital role in maintaining potassium ion recycling essential for auditory function, with mutations linked to hearing loss. Dysregulation of CLDN9 has also been implicated in cancer progression, where altered expression may influence metastasis, drug resistance, or immune evasion, particularly in gastric, ovarian, and hepatic cancers.
Recombinant CLDN9 protein is engineered in vitro using expression systems (e.g., mammalian, insect, or bacterial cells) to study its biological roles. It is purified with affinity tags (e.g., His-tag) and validated via SDS-PAGE, Western blot, or functional assays. Researchers employ this protein to investigate tight junction dynamics, develop monoclonal antibodies, or screen therapeutics targeting CLDN9-associated pathologies. Its applications extend to elucidating molecular mechanisms in hearing disorders and cancer biology, offering potential for diagnostic or therapeutic innovations. However, challenges remain in stabilizing its transmembrane structure and ensuring functional activity in experimental models.
×
